Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LMB-100 + SVP-rapa |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LMB-100 | RG7787|RO-6927005|RO6927005|LMB100 | LMB-100 is an immunotoxin that targets mesothelin, potentially resulting in antitumor activity (PMID: 27863199, PMID: 32611684). | ||
SVP-rapa | SEL-110|SEL110 | SVP-rapa is a drug comprised of synthetic vaccine particles that contain rapamycin, which blocks antibodies from forming upon treatment with immunogenic-type therapies (Cancer Res 2017;77(13 Suppl):Abstract nr 72). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03436732 | Phase I | LMB-100 + SVP-rapa | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | Terminated | USA | 0 |